 |
PDF »
October 30, 2007
Cougar Biotechnology to Present at Upcoming Investor Conferences
Los Angeles, CA, October 30, 2007 - Cougar Biotechnology, Inc. (OTCBB: CGRB) today announced that Alan H. Auerbach, Chief Executive Officer and President of Cougar, will be presenting at the following investor conferences:
- CIBC World Markets 18th Annual Healthcare Conference on Monday, November 5, at 10:55 a.m. EST at The Waldorf-Astoria Hotel in New York City
- Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference on Tuesday, November 6, at 12:20 p.m. EST at the New York Palace Hotel in New York City
At both presentations, Mr. Auerbach will provide a company overview and update on the status of Cougar's current clinical development programs. Live webcasts of these presentations will be accessible through the Investor Relations section of the company's Web site at www.cougarbiotechnology.com. The presentations will be archived on the Web site and available for 30 days.
About Cougar Biotechnology
Cougar Biotechnology, Inc. is a Los Angeles-based biotechnology company established to in-license and develop clinical stage drugs, with a specific focus on the field of oncology. Cougar's oncology portfolio includes CB7630, a targeted inhibitor of the 17-alpha hydroxylase/c17,20 lyase enzyme, which is currently being tested in Phase II clinical trials in prostate cancer; CB3304, an inhibitor of microtubule dynamics, which is currently in a Phase I trial in hematological malignancies and CB1089, an analog of vitamin D, which has been clinically tested in a number of solid tumor types.
Further information about Cougar Biotechnology can be found at www.cougarbiotechnology.com.
Contact
Alan H. Auerbach
Chief Executive Officer and President
+1 310-943-8040
ahauerbach@cougarbiotechnology.com
Mariann Ohanesian
Director of Investor Relations
+1 310-943-8040, Ext. 117
mohanesian@cougarbiotechnology.com
Russo Partners, LLC
David Schull
+1 212-845-4271
David.Schull@eurorscg.com
Andreas Marathovouniotis
+1 212-845-4253
Andreas.Marathis@eurorscg.com
Forward-Looking Statements:
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are often, but not always, made through the use of words or phrases such as "anticipates," "expects," "plans," "believes," "intends," and similar words or phrases. These forward-looking statements include, without limitation, statements related to benefits to be derived from Cougar’s drug development programs, including the potential advantages of CB7630 and its potential for use in the treatment of CRPC and in second line hormone and chemotherapy treatment settings. Such statements involve risks and uncertainties that could cause Cougar’s actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks and uncertainties inherent in clinical trials, and drug development and commercialization, including the uncertainty of whether results in testing of CB7630 will be predictive of results in later stages of development. For a discussion of these and other factors, please refer to Cougar’s annual report on Form 10-KSB for the year ended December 31, 2006 as well as other subsequent filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and Cougar undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
| | |
Cougar Biotechnology, Inc.
10990 Wilshire Blvd, Suite 1200
Los Angeles, CA 90024
(310) 943-8040 Main
(310) 943-8059 Fax |
